GANX

Eric I. Richman

Known title: CHIEF EXECUTIVE OFFICERCIK: 0001313876

Eric I. Richman's purchase track record

Eric I. Richman has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
7/1/2024GANX$21K+58.9%+94.6%
5/19/2022GANX$43K+41.5%+17.4%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

Gain Therapeutics Appoints CEO Gene Mack As Interim CFO. Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.

this person other insiders at GANX

Transaction History

GANX▲ Buy$6K
GANX▲ Buy$15K
GANX▲ Buy—
GANX▲ Buy$6K
GANX▲ Buy$26K
GANX▲ Buy$11K
GANX▲ Buy$39K

We use analytics to understand how market-wall is used. No personal data is sold.